Hospitals' New Normal Five Years After COVID: Managing Medical Equipment Amid a Record-Breaking Flu Season
HOUSTON, TEXAS / ACCESS Newswire / March 10, 2025 / The COVID-19 pandemic forced hospitals to rethink everything, including how they manage medical equipment-especially when facing patient surges like the current flu season, which has reached a 15-year high, with more than 33 million reported cases. Now, five years after the pandemic, healthcare providers are using a new approach to help ensure clinicians are prepared with life-saving equipment before they need it most.
With healthcare costs rising and unpredictable patient surges becoming the norm, hospitals are prioritizing flexible, data-driven equipment management strategies to help avoid equipment shortages and budget strains. More hospitals than ever are turning to US Med-Equip's rentals and ASAP Asset Management program, which offers strategic solutions and real-time equipment tracking to help optimize costs, improve care, and better prepare for ongoing and future health crises.
"The COVID-19 crisis underscored the need for scalable approaches to help hospitals ensure they have critical devices when and where they are needed," said Greg Salario, CEO of US Med-Equip. "When every second counts, no clinician wants to risk patient care because they don't have enough equipment."
One healthcare leader in a Northeast hospital recently highlighted the impact of US Med-Equip's support in a firsthand account.
"With the recent surge of Influenza, RSV, and COVID cases, we have had an increase in demand for ventilators and non-invasive BIPAP/CPAP to treat our critical patients. USME's ASAP Asset Management program has been so valuable and has come to our rescue with these cases! It's very much appreciated during this stressful time! The partnership and great teamwork of our two teams have given the best possible care to our patients!"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
29 minutes ago
- Indianapolis Star
ECM Announces PrintStator v8.3, Providing Innovators with the ‘World's Fastest Motor Design Platform'
NEEDHAM, MA / ACCESS Newswire ECM PCB Stator Tech has announced PrintStator v8.3, a major update to its award-winning Motor CAD platform. The new version enables electromagnetic motor designs and optimized datasheets in just seconds-now with automated 'smart' design validation and feedback. It's a game-changing leap in speed and interactivity for advanced motor development powered by ECM's patented PCB Stator technology. 'We're putting the most powerful motor design tool I've ever seen directly into the hands of innovators and engineers, ' said ECM CEO Brian Casey. 'This isn't just about speed-it's about redefining how, where, and how quickly electric motors can be designed and brought to life. At ECM, we're obsessed with continuous improvement and technological advancement. v8.3 is a major leap-but it's far from the finish line. We'll continue pushing the boundaries of what's possible with this best available motor technology.' From Award-Winning Beta to Real-World Adoption 2024 was a breakout year for ECM. After releasing the beta version of PrintStator, the software earned recognition from leading technology and engineering institutions-taking home awards from Automate, SXSW, CES, Design World and more. More importantly, ECM's technology began powering real commercial products, including a new direct-drive racing wheel designed in partnership with Thrustmaster -proving that PrintStator isn't just disruptive in theory, but in-market. ECM Engineers Interfacing with PrintStator What's New in PrintStator v8.3 The latest update introduces a suite of backend and usability improvements: 100x Faster Optimization – Electromagnetic simulations and motor performance datasheet generation now complete in as little as 1-2 seconds, presenting a 100x magnitude speed improvement that enables near real-time iteration and dramatically accelerates motor design workflows. From Simulation to Housing in Hours – Engineers can now move directly from optimized motor outputs to mechanical integration. PrintStator v8.3 automatically generates parametric models and CAM- and CAD-ready housing designs-cutting mechanical handoff times from weeks to hours. JSON-Based Optimizer Output – Optimization results are now delivered in a clean, machine-readable .json format-making it easier to integrate with external CNC tools, CAD workflows, and automated manufacturing systems. Enhanced Flux-in-the-Gap Modeling – Improved magnetic flux calculations within the motor air gap boost simulation accuracy without compromising speed. This update leverages robust parallelization techniques to increase model fidelity while maintaining near real-time compute performance. Global Production with Gerber Output – While not new to v8.3, PrintStator continues to support direct Gerber file export-enabling flexible, regionalized manufacturing through any global PCB fabrication house. This enables flexible, tariff-mitigating production through regionalized or onshore manufacturing. Early Work on AI Design Assistant – Development is underway on a generative, AI-guided motor design assistant-aimed at further accelerating concept iteration by building on ECM's existing constraint-driven design language. ECM's PrintStator software generates Gerber files that can be sent directly to PCB manufacturers for immediate production-resulting in fully optimized motor solutions. Looking Ahead: ECM's Roadmap Frontend Overhaul & Custom API Development With backend speed now at 'miracle mode,' ECM's software team is focused on a complete frontend overhaul-developing a more intuitive UI and a custom API that will give users greater control over the optimization process and enable future integration with industry-leading CAD/CAM SaaS platforms. 'We're redesigning the front-end experience to match the power of what's under the hood,' said Casey. 'When leading engineers can design PCB Stator motors directly inside their CAD environment, we'll unlock an entirely new level of technology adoption on a global scale.' Enabling Vertical Integration, Reshoring & Tariff Mitigation As PrintStator adoption grows, ECM is helping OEMs vertically integrate motor design and production-eliminating winding lines, reducing reliance on specialized labor, and enabling motors to be manufactured anywhere PCB fabs exist. This unlocks geographic flexibility, supports onshoring/reshoring strategies, and helps partners mitigate tariffs by building motors closer to point of use. Partner Enablement at Every Stage With this latest software update, ECM continues to support both new and existing partners in launching custom motor development projects using the PrintStator platform-from initial prototyping to global production. Alpha and Beta Software access for select partners is slated for release later this year, further expanding collaboration and design velocity across industries. 'We have clear visibility through partner engagements into a future where leading enterprises are vertically integrating their motor supply chains and disrupting legacy models. With major OEMs and new entrants adopting ECM's software and patented technology, we're not just powering innovation-we're enabling the franchising of next-generation motor OEMs. ECM is catalyzing a true paradigm shift in how electric motors are developed, sourced, and scaled,' Casey added. 'In 2025, ECM is already seeing adoption from global leaders in robotics, consumer appliances, haptics, gaming, HVAC, and pump manufacturing-all leveraging PrintStator at serious scale.' About ECM PCB Stator Tech ECM PCB Stator Tech delivers the only full-stack platform for electric motor innovation-empowering partners to design, prototype, and optimize next-generation PCB Stator motors with unprecedented precision and speed. With PrintStator Motor CAD and patented axial flux hardware, ECM enables the development of compact, efficient, and quiet motors that: Learn more about ECM's PCB Stator solutions and PrintStator Motor CAD platform at and in these videos: 'How Does a PCB Stator Work?' and ' A New Way to Build Motors Without Winding Lines ' Contact Information Sam Jones Director of Marketing and Communications sjones@ or explore PrintStator View the original press release on ACCESS Newswire
Scientific American
31 minutes ago
- Scientific American
Can You Still Get a COVID Vaccine This Fall? Here's What to Know
For the first time since the COVID vaccines became available in pharmacies in 2021, the average person in the U.S. can't count on getting a free annual shot against a disease that has been the main or a contributing cause of death for more than 1.2 million people around the country, including nearly 12,000 to date this year. 'COVID's not done with us,' says Jennifer Nuzzo, an epidemiologist at Brown University. 'We have to keep using the tools that we have. It's not like we get to forget about COVID.' In recent weeks, the Department of Health and Human Services, led by prominent antivaccine activist Robert F. Kennedy, Jr., has announced a barrage of measures that are likely to reduce COVID vaccine access, leading to a swirl of confusion about what will be available for the 2025–2026 season. HHS officials did not respond to a request for comment for this article. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Government officials appear to be limiting COVID shots to people who are aged 65 and older and to those who have certain preexisting health conditions—groups that have long been known to face a higher risk of developing severe COVID. Pregnant people and some children, meanwhile, appear to be explicitly excluded from access, despite plentiful evidence that vaccines are very safe and effective for them and that COVID infections can cause them significant harm. Scientific American spoke with clinicians and public health experts about the latest COVID vaccine recommendations, what access may look like this fall and how these policies might influence people's vaccination choices and health. What COVID vaccines will be manufactured this year? Public health experts are monitoring a strain of the COVID-causing virus SARS-CoV-2 called NB.1.8.1, which was first detected early this year and last month became responsible for one in 10 COVID cases globally. So far, the new variant has mostly been reported in Asia and Europe. But it has also been picked up in airport surveillance in multiple U.S. states, says Peter Chin-Hong, an infectious disease physician and a professor of medicine at the University of California, San Francisco. The emergence of a new variant isn't surprising, particularly at this time of year, Chin-Hong says. 'It's kind of acting like clockwork—maybe this might be the variant of the summer,' he adds. Still, NB.1.8.1 has led to concerns about a potential surge in cases—although Chin-Hong and other scientists don't have any evidence so far that it causes more serious disease than other currently circulating strains. 'All of these new variants, they might be more transmissible, they might be more immune evasive, but I've seen no data whatsoever that suggests that they're more pathogenic,' says Angela Rasmussen, a virologist at the University of Saskatchewan. Within the U.S., a strain called LP.8.1 has been the most common one detected since March. Both NB.1.8.1 and LP.8.1 are among the alphabet soup of strains that descended from a key ancestor lineage called Omicron JN.1, which dominated U.S. cases by early 2024. Current vaccines target this category of strains. And in May a Food and Drug Administration panel determined that, this year, vaccine producers should again tailor their shots to a single strain within the JN.1 lineage—preferably LP.8.1. What's going on with COVID vaccine policy? Strain selection aside, the recent messaging and decision-making on vaccine policy for COVID and beyond have been chaotic, with various governmental groups and officials announcing different access guidelines and restrictions. 'The situation we're in right now is nuts,' says Nuzzo, referring to the fact that agency leaders have sidestepped the formal science committees that traditionally make vaccine-related decisions. 'We don't change vaccine policy on a willy-nilly basis. There's an incredible amount of nuance, and all of the data need to be considered.' But on June 9 Kennedy took a major step against this evidence-driven decision-making process by firing the entire CDC Advisory Committee on Immunization Practices (ACIP). Kennedy announced the committee rehaul in a Wall Street Journal op-ed, in which he alleged there were 'persistent conflicts of interest' among committee members. According to a recent HHS statement, new committee members are under consideration, and the group will still meet as scheduled from June 25 to 27. ACIP has traditionally been particularly important because any vaccine it recommends must be fully paid for by health insurance companies—a condition that greatly determines real-world access. It's unclear what the committee's overhaul will mean for COVID vaccine access in particular. Another concern is that Kennedy announced in late April that HHS would implement a policy requiring all 'new' vaccines—including updated versions of existing ones, such as COVID shots—to be tested against a placebo. The original COVID vaccines were tested in just this manner. But conducting similar tests when an effective and very safe vaccine already exists would be not only unethical for researchers but also expensive and time-consuming for manufacturers. It remains unclear when the new policy will take effect. What does this mean for COVID vaccine access this fall? If you are 65 years old or older, you should be able to get a COVID shot as you have in recent years. If you have an underlying condition such as cancer, diabetes, or heart or lung problems, you may also be able to get a COVID shot as usual. These issues and several others are on the CDC's list of conditions that leave people more vulnerable to severe disease, and this list is included in the description of the new regulatory framework. One 2021 study looked at many (but not all) of the conditions on the list and estimated that three in four U.S. adults has at least one. People are allowed to self-disclose a preexisting condition at pharmacies without a prescription or doctor's note. That list could also be expanded later if new research finds other risk factors that increase people's risk of severe COVID, says Jacinda Abdul-Mutakabbir, a clinical pharmacist and an assistant professor at the University of California, San Diego. But there's also a chance that qualifying conditions may be reduced instead. For example, current or recent pregnancy is included in the CDC's existing list, but HHS officials announced in late May that the COVID vaccine would no longer be recommended for pregnant people. Data have shown that COVID may cause various complications during pregnancy —increasing the risk that the pregnant person may require emergency care, be put on a ventilator or die. The newborn child of an infected person is also more likely to be born preterm or to have low birth weight. And babies younger than six months old—who are ineligible for vaccination because of their immature immune system—have the highest rates COVID hospitalization after adults aged 75 and older. In contrast, evidence from people vaccinated during pregnancy show that newborns receive protective immunity through antibodies that cross the placenta and are found in breast milk, Chin-Hong explains. Healthy children also face new restrictions to COVID vaccine access: The shot is now only recommended to them based on 'shared clinical decision-making,' according to the vaccine schedules released by the CDC last month. This means parents must consult with a health practitioner about whether to vaccinate such children. Experts worry about the consequences of restricting access for kids. Children under age 18 make up a smaller percentage of COVID hospitalizations and deaths. But that doesn't mean zero risk, Chin-Hong says. 'We know that COVID still kills kids,' he says. 'No death of a child is a good death—and these are all preventable.' 'Because children and pregnant people are considered vulnerable populations, they were not included in the original studies that were done for the COVID vaccines,' Abdul-Mutakabbir says. But five years' worth of real-world vaccine data from these groups show the health benefits. 'We do see effectiveness and safety in these vaccines,' she says. It's still possible that the late June ACIP meeting will shift the landscape again. But if you want a COVID vaccine this fall and don't meet current guidelines, you may still be able to request a shot. Your insurance may not pay for it, however, leaving you to risk a price tag of around $200. 'Insurance companies or providers are only required to pay for vaccines that are listed as recommended by the CDC,' Abdul-Mutakabbir says. Full, partial or no-cost coverage for nonrecommended vaccines is at the insurance provider's discretion. Any changes to coverage—and the times at which those changes are announced—will vary among programs, including private and governmental ones, such as the federal-state program Medicaid and the federal program Medicare. Until then, Chin-Hong and Abdul-Mutakabbir say, the COVID vaccines released in the fall of 2024 are still recommended and available to people who haven't already had one. And as of April 26, only 23 percent of adults and 13 percent of children in the U.S. had received the shot. 'If you are nervous about the surge or planning summer travel, I would recommend' getting the vaccine, Abdul-Mutakabbir says. The larger fight over vaccines For Rasmussen, the confusion over COVID shots signals the beginning of a longer tug-of-war—with Kennedy's HHS on one end. 'I think I know what their plan is, and it's to reduce access to vaccines in general,' she says. 'In my view, this is an incremental step in a larger attack on vaccination in general.' She encourages people worried about vaccine restrictions—and about the role of science in making these decisions—to call their congressional legislators. 'A lot of people speaking out is what is needed right now to make a big difference here,' she says. Abdul-Mutakabbir also hopes people continue to seek vaccines for COVID and other diseases—especially while they are still easily available. 'It's important that we consider the things that we can protect ourselves against,' Abdul-Mutakabbir says. 'Should you have a barrier with getting a COVID vaccine, guess what? There's no change to the flu vaccine; there's no changes to the pneumococcal recommendations; there's no change to measles, mumps, rubella vaccine. Get the vaccines that we can get.'
Yahoo
44 minutes ago
- Yahoo
TEXAS DIVISIONAL COURT AWARDS RIFT ENERGY A US$ 36 MILLION JUDGMENT AGAINST FORMER CEO FRED ZAZISKI
TORONTO, June 10, 2025 /CNW/ - Rift Energy Corp ("Rift Energy") is pleased to announce that it has today received a certified copy of the Texas Divisional Court decision awarding it US$36 million in actual damages against its former CEO, Fred Zaziski. Furthermore, the court ordered the relinquishment of any equity interest in the company or debt securities held by Zaziski. "The decision is a result of nearly a decade-long battle between the company and its former boss, and this decision now clears the way for the company to move forward with the development of its East African hydrocarbon project in Kenya," says Peter Deeb, Lead Director and Co-Founder of RIFT Energy. "To date, the company has invested more than $20 million in Kenya's Block L-19, resulting in what appears to be a sizeable oil and gas opportunity. The company plans to pursue a capital raise from its founders and institutional investors to move forward with a drilling program in short order." In 2014, Rift Energy completed a 2D Seismic Program that produced high-quality data. Numerous leads and prospects that correlate to Rift Energy's proprietary Aerial Gravity & Magnetic Survey and Geochemical Survey, both of which were completed during 2013. About Rift Energy Rift Energy is a privately owned early-stage oil and gas exploration company that is focused on acquiring oil and gas projects in East Africa. Rift Energy's strategy is to identify under-explored assets with high upside that, when exploited, will yield substantial value for its shareholders. Its Board of Directors includes John H. Sununu, former Governor of New Hampshire and Chief of Staff for President George H.W. Bush; Kenneth Hern, Director of Armada Oil Inc.; and Peter Deeb, Chairman of Hampton Securities Ltd. About Block L19, Kenya Block L19 encompasses approximately 12,000 KM2 (2.9 million acres) onshore in southeast Kenya. Rift Energy is in advanced discussions with the Government of Kenya to facilitate the next phase of development. There has been only one well drilled on Block L19 to date, the Ria Kalui 1 well, which was drilled off structure to a depth of 1,538 meters in 1962 and was plugged after encountering oil shows in the Karoo formation. Contact information:Rift Energy Corp. Peter Deeb Dennis Tatum 141 Adelaide Street West, Suite 1800 Lead Director CFO & VP Finance Toronto, Ontario CANADA M5H 3L5 dtatum@ (416) 317-3967 The common shares of Rift Energy has not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and all applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy the common shares in the United States or to, or for the account or benefit of, U.S. persons. SOURCE RIFT ENERGY View original content to download multimedia:
